|Tested species reactivity||Human, Mouse|
|Published species reactivity||Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant protein fragment corresponding to a region within amino acids 1 and 200 of Human Proteasome 20S alpha 5|
|Purification||Antigen affinity chromatography|
|Storage buffer||0.1M tris glycine, pH 7, with 10% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100-1:1000|
|Western Blot (WB)||1:500-1:5000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunocytochemistry (ICC)||See 1 publications below|
PA5-27962 targets Proteasome 20S alpha 5 in IF, IHC (P), and WB applications and shows reactivity with Human and mouse samples.
The PA5-27962 immunogen is recombinant protein fragment corresponding to a region within amino acids 1 and 200 of Human Proteasome 20S alpha 5.
The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the peptidase T1A family, that is a 20S core alpha subunit.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.
PA5-27962 was used in immunocytochemistry to study the therapeutic potential of tumor-associated embryonic antigen-expressing vaccines that target CCR6
|Biragyn A,Schiavo R,Olkhanud P,Sumitomo K,King A,McCain M,Indig FE,Almanzar G,Baatar D||Journal of immunology (Baltimore, Md. : 1950) (179:1381)||2007|